Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new outlooks.

Abu-Elmagd KM, Mazariegos G, Costa G, Soltys K, Bond G, Sindhi R, Green M, Jaffe R, Wu T, Koritsky D, Matarese L, Schuster B, Martin L, Dvorchik I, Nalesnik MA.

Transplantation. 2009 Oct 15;88(7):926-34. doi: 10.1097/TP.0b013e3181b7509c.

PMID:
19935465
2.

Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation.

Vianna RM, Mangus RS, Fridell JA, Weigman S, Kazimi M, Tector J.

Transplantation. 2008 May 15;85(9):1290-3. doi: 10.1097/TP.0b013e31816dd450.

PMID:
18475186
3.

Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.

Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, Crouch J, Bia MJ, Kliger AS, Lorber MI.

Transplantation. 1997 Sep 27;64(6):848-52.

PMID:
9326409
4.

Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.

Cacciarelli TV, Green M, Jaffe R, Mazariegos GV, Jain A, Fung JJ, Reyes J.

Transplantation. 1998 Oct 27;66(8):1047-52.

PMID:
9808490
5.

Evolutionary experience with immunosuppression in pediatric intestinal transplantation.

Bond GJ, Mazariegos GV, Sindhi R, Abu-Elmagd KM, Reyes J.

J Pediatr Surg. 2005 Jan;40(1):274-9; discussion 279-80.

PMID:
15868597
6.

Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.

Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW.

Transplantation. 2003 Nov 15;76(9):1289-93.

PMID:
14627905
7.

Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.

Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, Reding R, Janssen M, Buts JP, Otte JB.

Transplantation. 1997 Nov 27;64(10):1438-42.

PMID:
9392308
8.

Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.

Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR Jr.

Transplantation. 1996 Aug 15;62(3):370-5.

PMID:
8779685
9.

Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University.

Gao SZ, Chaparro SV, Perlroth M, Montoya JG, Miller JL, DiMiceli S, Hastie T, Oyer PE, Schroeder J.

J Heart Lung Transplant. 2003 May;22(5):505-14.

PMID:
12742411
10.

Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center.

Quintini C, Kato T, Gaynor JJ, Ueno T, Selvaggi G, Gordon P, McLaughlin G, Tompson J, Ruiz P, Tzakis A.

Transplant Proc. 2006 Jul-Aug;38(6):1755-8.

PMID:
16908272
11.

Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.

McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martín MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW.

Transplantation. 1998 Dec 27;66(12):1604-11. Erratum in: Transplantation 1999 Sep 27;68(6):909. Lee GS [corrected to Kim GS].

PMID:
9884246
12.

The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.

Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW, Ament ME.

Transplantation. 2000 Jul 15;70(1):94-9.

PMID:
10919581
13.

Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.

Ellis D, Jaffe R, Green M, Janosky JJ, Lombardozzi-Lane S, Shapiro R, Scantlebury V, Vivas C, Jordan ML.

Transplantation. 1999 Oct 15;68(7):997-1003.

PMID:
10532541
14.

Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.

Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M.

J Pediatr Gastroenterol Nutr. 2004 Feb;38(2):198-203.

PMID:
14734884
15.

Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.

Newell KA, Alonso EM, Kelly SM, Rubin CM, Thistlethwaite JR Jr, Whitington PF.

J Pediatr. 1997 Jul;131(1 Pt 1):98-104.

PMID:
9255199
16.

The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.

Kogan-Liberman D, Burroughs M, Emre S, Moscona A, Shneider BL.

J Pediatr Gastroenterol Nutr. 2001 Oct;33(4):445-9.

PMID:
11698761
17.

Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.

Berney T, Delis S, Kato T, Nishida S, Mittal NK, Madariaga J, Levi D, Nery JR, Cirocco RE, Gelman B, Ruiz P, Tzakis AG.

Transplantation. 2002 Oct 15;74(7):1000-6.

PMID:
12394845
18.

Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.

Zanfi C, Lauro A, Cescon M, Dazzi A, Ercolani G, Grazi GL, Zanello M, Vivarelli M, Del Gaudio M, Ravaioli M, Cucchetti A, Vetrone G, Tuci F, Di Gioia P, Lazzarotto T, D'Errico A, Bagni A, Faenza S, Siniscalchi A, Pironi L, Pinna AD.

Transplant Proc. 2010 Jan-Feb;42(1):35-8. doi: 10.1016/j.transproceed.2009.12.019.

PMID:
20172276
19.

Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.

Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA.

Transplantation. 1993 Jul;56(1):88-96.

PMID:
8333073
20.

Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age.

Tjon AS, Sint Nicolaas J, Kwekkeboom J, de Man RA, Kazemier G, Tilanus HW, Hansen BE, van der Laan LJ, Tha-In T, Metselaar HJ.

Liver Transpl. 2010 Jul;16(7):837-46. doi: 10.1002/lt.22064.

Supplemental Content

Support Center